Schering AG encouraged by new cancer drug data
The data indicate a favorable tolerability profile, with evidence of anti-tumor activity in patients with advanced disease. In the phase I trial 52 patients with advanced solid tumors
US-based biotechnology company Superluminal Medicines has completed a $60m Series B financing round to support its research into therapies for rare genetic forms of obesity and hypothalamic obesity.
The collaboration is designed to combine Lexicon’s target discovery and biotherapeutics capabilities with Organon’s clinical development, biologics manufacturing and commercialization franchise to accelerate the development of novel therapeutic
Trizivir (abacavir sulfate, lamivudine, and zidovudine) is a fixed-dose-combination tablet containing the three nucleoside reverse transcriptase inhibitors Epivir (lamivudine, 3TC), Retrovir (zidovudine, ZDV) and Ziagen (abacavir sulfate, ABC).